In an interview segment with Kirby, she described her views on the need for future research into povorcitinib for hidradenitis suppurativa patients, as well as her outlook on treatment.
Tim Smith
Advertisement
Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at [email protected].
Articles by Tim Smith
In the interview, Kirby discussed recent trial data on povorcitinib indicating significant decreases in total abscess and inflammatory nodule count for hidradenitis suppurativa patients.
Chovatiya discussed his Winter Clinical Miami presentation, common concerns over black box warnings for JAK inhibitors, and unmet needs of alopecia areata patients.
In his latest HCPLive interview, regarding a presentation at Winter Clinical Miami, Chovatiya spoke about recent JAK inhibitor developments, alopecia areata, baricitinib, and more.
In her latest HCPLive interview, Ablon discusses her Winter Clinical Miami dermatology conference presentation ‘Evaluating the Aesthetic Patient’ and its biggest takeaways.
In another segment of her interview with HCPLive, Graber explored some of the latest treatment developments for acne and rosacea covered in her 2023 Winter Clinical Miami presentation.
In an HCPLive interview on her Winter Clinical Miami presentation, Graber describes several new developments in the dermatology space regarding acne and rosacea treatments.
In another segment of his interview, Mark Lebwohl, MD, discussed the various ways to address different psoriasis patients depending on their backgrounds with obesity, cancer, and psoriatic arthritis.
In his recent interview, Mark Lebwohl, MD, spoke about his Winter Clinical Miami presentation titled ‘Psoriasis: Which Drug for Which Patient?’ and some of its highlights.
In an interview with Maria Teresa García-Romero, MD, MPH, a discussion was held regarding the need for a morphea severity tool for pediatric patients.
New research into global trends in atopic dermatitis over 3 decades assessed regional and income differences in adolescent eczema patients.
Mental health outcomes for those with hidradenitis suppurativa who have had a previous surgery were explored in recent research.
Recent findings found that an association existed between late-in-life depression and air pollution over time for the older US population.
In another interview segment, Karan Lal, DO, MS, spoke on the side effects of JAK inhibitors and on the FDA approval of abrocitinib for younger atopic dermatitis patients.
During his latest HCPLive interview, Karan Lal, DO, describes some of the major takeaways from his presentations at the South Beach Symposium, including information on atopic dermatitis.
New research explored associations between lesions resulting from Degos and diffuse cutaneous systemic sclerosis.
An interview segment with Alexa Kimball, MD, MPH, in which she describes further updates on 52 week trial data in the SUNRISE and SUNSHINE trials for HS.
A recent interview with Alexa Kimball, MD, MPH, regarding recent data from the SUNRISE and SUNSHINE studies on secukinumab for HS patients.
In recent phase 2 trial data, a monoclonal antibody called vixarelimab showed strong results for prurigo nodularis treatment.
Research was conducted into the development of a tool for assessing morphea disease severity in pediatric patients.
New research into patient-focused deprescribing strategies for those dealing with the effects of polypharmacy in hospital and post-acute care facilities.
New research was conducted regarding air pollution and other elements affecting asthma cases in urbanized settings.
New research into the use of ustekinumab compared to other treatments for psoriasis sheds light on risk for outpatient infections.
New research into the nursing home CMS rating system suggests that a revision may improve the public’s information access.
New research was found on alcohol consumption as a modifiable risk factor in dementia, in a study out of South Korea.
An interview with Victoria Barrio, MD, and Fabiana Castro Porto Silva Lopes, MD, about the Society for Pediatric Dermatology and its efforts to address diversity in the dermatology field.
A recent study highlighted new information on racial disparities in health care for Black and Hispanic pediatric patients with atopic dermatitis.
New research into egg, peanut allergies and sensitization raised questions about allergy incidence rates and early exposure.
A list of the top stories covered this week in the dermatology field, with data on breakthroughs, new research, and advanced treatment options.
In recent research into alopecia areata treatments, selective JAK1 inhibition was tested as a means for restoring hair growth.
Advertisement
Advertisement
Advertisement
Trending on HCPLive
1
Omalizumab-Facilitated OIT Enables Maintenance Dosing in Food Allergy
2
After Sickle Cell Gene Therapy, What Comes Next?
3
VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes
4
Namilumab Fails to Meet Primary End Point in Pulmonary Sarcoidosis
5